The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. The index has shown a price gain of 60.65% this year. Over the last six months, there has been a stronger performance of -14.78%. The price of ANAB fallen by 2.60% during the last 30 days period. For the last 5-days stocks have improved 1.77%.
AnaptysBio Inc’s stock has seen a rocky market performance.
52-week price history of ANAB Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. AnaptysBio Inc’s current trading price is -48.51% away from its 52-week high, while its distance from the 52-week low is 74.20%. The stock’s price range over this timeframe has been between $12.21 and $41.31. The shares of the Healthcare sector company recorded a trading volume of approximately 1.97 million for the day, which was comparatively higher than the average daily volume of 0.74 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
AnaptysBio Inc (ANAB) has experienced a quarterly rise of 26.99% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 624.92M and boasts a workforce of 136 employees.
How Moving Averages and Trading Volume Data Work Together
ANAB’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for ANAB stands at 10.17. Similarly, the long-term debt-to-equity ratio is also 10.11.
